GRTX News and Press, Galera Therapeutics Inc. From 05/16/22

Galera Therapeutics (NASDAQ:GRTX) said it intends to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) by the end of 2022 for avasopasem manganese (avasopasem) to treat radiotherapy-induced severe oral mucositis (SOM) in patients with locally advanced hea...

Company plans to submit a New Drug Application (NDA) for avasopasem for the treatment of radiotherapy-induced severe oral mucositis (SOM) by end of 2022 Data from its Phase 3 ROMAN trial of avasopasem for SOM will be presented in an oral presentation at the upcoming 2022 America...

MALVERN, Pa., May 16, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today anno...

Galera Therapeutics (NASDAQ:GRTX) said its drug avasopasem helped reduce severe incidents of esophagitis in patients with lung cancer receiving concurrent chemoradiotherapy in a mid-stage study. Esophagitis is an inflammation of the lining of the esophagus, the tube connecting the throat...

Innoviz Technologies (INVZ) +22% after selected to be a LiDAR supplier for large vehicle maker. Redbox Entertainment (RDBX) +20%. Hilltop Holdings (HTH) +14% on commencing offer to repurchase up to $400M of its stock. Companhia Energetica (CIG) +14%. BlueCity Holdings (BLC...

Incidence of Grade 3 esophagitis substantially reduced in patients treated with avasopasem compared to literature No Grade 4 or 5 esophagitis in patients treated with avasopasem MALVERN, Pa, May 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clini...

MALVERN, Pa., April 27, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today an...

Galera Therapeutics is developing drugs that reduce side effects from anti-cancer radiotherapy and improve the treatment outcome. Clinical trial data have demonstrated statistically significant efficacy for the Avasopasem drug against severe oral mucositis. A pending meeting with ...

Galera Therapeutics press release (NASDAQ:GRTX): Q4 GAAP EPS of -$0.64 beats by $0.10. As of December 31, 2021, the company had cash, cash equivalents and short-term investments of $71.2 million. Shares +6.25% PM. For further details see: Galera Therapeutics GAAP EPS of -$0.64 beats by ...

Positive Phase 3 ROMAN trial of avasopasem for severe oral mucositis met primary and secondary endpoint; Company intends to meet with FDA in 2022 about NDA submission Data readouts from AESOP in esophagitis and GRECO-1 in lung cancer expected in 1H 2022 Strong cash posit...